Table 1
Patient responses to the MEND treatment protocol [3]
| Patient | Diagnosis | ApoE Genotype | Treatment Outcome1 |
|---|---|---|---|
| 66yoM | MCI, type 1 (inflammatory) | 3/4 | Marked subjective improvement, hippocampal volume increase 17th->75th %ile |
| 69yoM | AD, type 2 (atrophic) | 3/4 | Marked subjective improvement, quantitative neuropsychological testing improvement |
| 49yoF | MCI, type 2 (and possibly type 3 (toxic)) | 4/4 | Marked subjective improvement, neuropsychological testing improvement |
| 49yoF | MCI, type 2 | 2/4 | Marked subjective improvement, neuropsychological testing improvement |
| 55yoF | MCI, type 2 | 4/4 | Marked subjective improvement, neuropsychological testing improvement |
| 74yoM | AD, type 1 | 4/4 | Subjective improvement, MMSE 23->30 |
| 62yoM | AD, type 1.5 (glycotoxic) | 4/4 | Subjective improvement, MMSE 22->29 |
| 68yoM | MCI, type 1.5 | 3/4 | Subjective improvement, neuropsychological testing improvement |
| 54yoF | AD, type 3 | 3/3 | Clear subjective improvement, MoCA 19->21 |
| 54yoF | MCI, type 2 | 4/4 | Subjective improvement, neuropsychological testing improvement |